Adaptive Biotechnologies Corporation
ADPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $178,957 | $170,276 | $185,308 | $154,344 |
| % Growth | 5.1% | -8.1% | 20.1% | – |
| Cost of Goods Sold | $72,080 | $75,553 | $57,909 | $49,301 |
| Gross Profit | $106,877 | $94,723 | $127,399 | $105,043 |
| % Margin | 59.7% | 55.6% | 68.7% | 68.1% |
| R&D Expenses | $102,953 | $122,117 | $141,756 | $142,343 |
| G&A Expenses | $72,806 | $83,934 | $88,527 | $74,502 |
| SG&A Expenses | $157,565 | $172,513 | $184,130 | $169,967 |
| Sales & Mktg Exp. | $84,759 | $88,579 | $95,603 | $95,465 |
| Other Operating Expenses | $8,908 | $27,128 | $1,699 | $1,699 |
| Operating Expenses | $269,426 | $321,758 | $327,585 | $314,009 |
| Operating Income | -$162,549 | -$227,035 | -$200,186 | -$208,966 |
| % Margin | -90.8% | -133.3% | -108% | -135.4% |
| Other Income/Exp. Net | $2,954 | $1,731 | -$182 | $1,668 |
| Pre-Tax Income | -$159,595 | -$225,304 | -$200,368 | -$207,298 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$159,492 | -$225,250 | -$200,191 | -$207,279 |
| % Margin | -89.1% | -132.3% | -108% | -134.3% |
| EPS | -1.08 | -1.56 | -1 | -1.46 |
| % Growth | 30.8% | -56% | 31.5% | – |
| EPS Diluted | -1.08 | -1.56 | -1 | -1.46 |
| Weighted Avg Shares Out | 147,102 | 144,383 | 142,516 | 140,355 |
| Weighted Avg Shares Out Dil | 147,102 | 144,383 | 142,516 | 140,355 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,534 | $15,531 | $4,056 | $1,668 |
| Interest Expense | $11,580 | $13,800 | $4,238 | $0 |
| Depreciation & Amortization | $19,256 | $22,231 | $20,920 | $13,953 |
| EBITDA | -$128,759 | -$189,273 | -$175,210 | -$193,345 |
| % Margin | -71.9% | -111.2% | -94.6% | -125.3% |